Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Vet Pharmacol Ther ; 40(5): 447-453, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27891622

RESUMEN

The safety profile of afoxolaner (an isoxazoline molecule) when combined with milbemycin oxime (a macrocyclic lactone) was evaluated according to the regulatory requirements when administered six times orally in a soft chewable formulation at a dose of at least 1×, 3×, or 5× the maximum exposure dose in 8-week-old Beagle dogs. Thirty-two healthy puppies (16 males and 16 females) were enrolled and allocated randomly to one of four treatment groups. Three doses were administered at 28-day intervals (Days 0, 28, and 56), followed by three additional doses administered with 14-day intervals (Days 84, 98, and 112). The study ended on Day 126. Treatment groups were as follows: Group 1: untreated, sham-dosed control; Group 2: afoxolaner/milbemycin oxime chews administered at a dose of at least 5 and 1 mg/kg, respectively (1×); Group 3: afoxolaner/milbemycin oxime chews administered at a dose of at least 15 and 3 mg/kg, respectively (3); and Group 4: afoxolaner/milbemycin oxime chews administered at a dose of at least 25 and 5 mg/kg, respectively (5×). All dogs were examined for general health twice a day beginning on Day -14. Physical examinations, and blood collections for clinical pathology analysis and afoxolaner and milbemycin oxime plasma concentrations, were performed throughout the study. No afoxolaner/milbemycin oxime treatment-related changes were observed in growth, physical variables, clinical pathology variables, or tissues examined histologically. No clinically relevant or statistically significant health abnormalities related to the administration of afoxolaner/milbemycin oxime were observed. No signs of macrocyclic lactone sensitivity were observed at any time during the study. Vomiting and diarrhea were observed sporadically across all groups including the controls. Based upon the results of this study, afoxolaner/milbemycin oxime soft chewables were shown to be safe when administered repeatedly at up to 5× the maximum exposure dose in dogs as young as 8 weeks of age.


Asunto(s)
Antiparasitarios/administración & dosificación , Enfermedades de los Perros/prevención & control , Isoxazoles/administración & dosificación , Macrólidos/administración & dosificación , Naftalenos/administración & dosificación , Administración Oral , Animales , Antiparasitarios/efectos adversos , Perros , Femenino , Isoxazoles/efectos adversos , Macrólidos/efectos adversos , Masculino , Naftalenos/efectos adversos
2.
J Vet Pharmacol Ther ; 40(1): 35-43, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27604405

RESUMEN

The pharmacokinetics of afoxolaner and milbemycin oxime (A3 and A4 forms) in dogs were evaluated following the oral administration of NexGard Spectra® (Merial), a fixed combination chewable formulation of these two active pharmaceutical ingredients. Absorption of actives was rapid at levels that provide the minimum effective doses of 2.5 mg/kg and 0.5 mg/kg of afoxolaner and milbemycin oxime, respectively. The time to maximum afoxolaner plasma concentrations (tmax ) was 2-4 h. The milbemycin tmax was 1-2 h. The terminal plasma half-life (t1/2 ) and the oral bioavailability were 14 ± 3 days and 88.3% for afoxolaner, 1.6 ± 0.4 days and 80.5% for milbemycin oxime A3 and 3.3 ± 1.4 days and 65.1% for milbemycin oxime A4. The volume of distribution (Vd ) and systemic clearance (Cls) were determined following an IV dose of afoxolaner or milbemycin oxime. The Vd was 2.6 ± 0.6, 2.7 ± 0.4 and 2.6 ± 0.6 L/kg for afoxolaner, milbemycin oxime A3 and milbemycin oxime A4, respectively. The Cls was 5.0 ± 1.2, 75 ± 22 and 41 ± 12 mL/h/kg for afoxolaner, milbemycin oxime A3 and milbemycin oxime A4, respectively. The pharmacokinetic profile for the combination of afoxolaner and milbemycin oxime supports the rapid onset and a sustained efficacy for afoxolaner against ectoparasites and the known endoparasitic activity of milbemycin oxime.


Asunto(s)
Acaricidas/farmacocinética , Enfermedades de los Perros/tratamiento farmacológico , Infestaciones por Pulgas/veterinaria , Insecticidas/farmacocinética , Isoxazoles/farmacocinética , Macrólidos/farmacocinética , Naftalenos/farmacocinética , Infestaciones por Garrapatas/veterinaria , Acaricidas/administración & dosificación , Acaricidas/sangre , Acaricidas/uso terapéutico , Administración Intravenosa/veterinaria , Administración Oral , Animales , Disponibilidad Biológica , Enfermedades de los Perros/parasitología , Perros , Combinación de Medicamentos , Femenino , Infestaciones por Pulgas/tratamiento farmacológico , Insecticidas/administración & dosificación , Insecticidas/sangre , Insecticidas/uso terapéutico , Isoxazoles/administración & dosificación , Isoxazoles/sangre , Isoxazoles/uso terapéutico , Macrólidos/administración & dosificación , Macrólidos/sangre , Macrólidos/uso terapéutico , Masculino , Naftalenos/administración & dosificación , Naftalenos/sangre , Naftalenos/uso terapéutico , Infestaciones por Garrapatas/tratamiento farmacológico
3.
Cell Death Differ ; 9(7): 734-41, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12058278

RESUMEN

The goal of the current study was to determine the roles of ATP content, endoplasmic reticulum (ER) Ca(2+) stores, cytosolic free Ca(2+) (Ca(2+)(f)) and calpain activity in the signaling of rabbit renal proximal tubular (RPT) cell death (oncosis). Increasing concentrations (0.3-10 microM) of the mitochondrial inhibitor antimycin A produced rapid ATP depletion that correlated to a rapid and sustained increase in Ca(2+)(f), but not phospholipase C activation. The ER Ca(2+)-ATPase inhibitors thapsigargin (5 microM) or cyclopiazonic acid (100 microM) alone produced similar but transient increases in Ca(2+)(f). Pretreatment with thapsigargin prevented antimycin A-induced increases in Ca(2+)(f) and antimycin A pretreatment prevented thapsigargin-induced increases in Ca(2+)(f). Calpain activity increased in conjunction with ER Ca(2+) release. Pretreatment, but not post-treatment, with thapsigargin or cyclopiazonic acid prevented antimycin A-induced cell death. These data demonstrate that extensive ATP depletion signals oncosis through ER Ca(2+) release, a sustained increase in Ca(2+)(f) and calpain activation. Depletion of ER Ca(2+) stores prior to toxicant exposure prevents increases in Ca(2+)(f) and oncosis.


Asunto(s)
Apoptosis , Señalización del Calcio , Calpaína/metabolismo , Retículo Endoplásmico/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Antimicina A/farmacología , Calcio/metabolismo , ATPasas Transportadoras de Calcio/antagonistas & inhibidores , Células Cultivadas , Estrenos/farmacología , Indoles/farmacología , Túbulos Renales Proximales/citología , Pirrolidinonas/farmacología , Conejos , Tapsigargina/farmacología , Fosfolipasas de Tipo C/antagonistas & inhibidores
4.
Am J Physiol Renal Physiol ; 281(4): F728-38, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11553520

RESUMEN

The goals of this study were to determine 1) the expression of calpain isoforms in rabbit renal proximal tubules (RPT); 2) calpain autolysis and translocation, and calpastatin levels during RPT injury; and 3) the effect of a calpain inhibitor (PD-150606) on calpain levels, mitochondrial function, and ion transport during RPT injury. RT-PCR, immunoblot analysis, and FITC-casein zymography demonstrated the presence of only mu- and m-calpains in rabbit RPT. The mitochondrial inhibitor antimycin A decreased RPT mu- and m-calpain and calpastatin levels in conjunction with cell death and increased plasma membrane permeability. No increases in either mu- or m-calpain were observed in the membrane nor were increases observed in autolytic forms of either mu- or m-calpain in antimycin A-exposed RPT. PD-150606 blocked antimycin A-induced cell death, preserved calpain levels in antimycin A-exposed RPT, and promoted the recovery of mitochondrial function and active Na+ transport in RPT after hypoxia and reoxygenation. The present study suggests that calpains mediate RPT injury without undergoing autolysis or translocation, and ultimately they leak from cells subsequent to RPT injury/death. Furthermore, PD-150606 allows functional recovery after injury.


Asunto(s)
Calpaína/metabolismo , Muerte Celular/fisiología , Isoenzimas/metabolismo , Túbulos Renales Proximales/metabolismo , Túbulos Renales Proximales/patología , Acrilatos/farmacología , Animales , Antibacterianos/farmacología , Antimicina A/farmacología , Autólisis/metabolismo , Transporte Biológico Activo/efectos de los fármacos , Transporte Biológico Activo/fisiología , Proteínas de Unión al Calcio/metabolismo , Calpaína/análisis , Calpaína/genética , Caseínas , Muerte Celular/efectos de los fármacos , Membrana Celular/enzimología , Inhibidores de Cisteína Proteinasa/farmacología , Citosol/enzimología , Femenino , Fluoresceína-5-Isotiocianato , Colorantes Fluorescentes , Regulación Enzimológica de la Expresión Génica , Immunoblotting , Isoenzimas/genética , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Conejos , Daño por Reperfusión/metabolismo , Daño por Reperfusión/patología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sodio/metabolismo
5.
J Pharmacol Exp Ther ; 294(3): 1083-7, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10945863

RESUMEN

Inhibitors of calpains, calcium-activated neutral proteases, protect against cell death produced by anoxia and a variety of toxicants both in vitro and in vivo. The problems with known calpain inhibitors are a lack of specificity, low membrane permeability, and/or low potency. The goal of this study was to determine the effects of seven novel dipeptide and tripeptide calpain inhibitors on calpain activity and antimycin A-induced cell death in rabbit renal proximal tubule (RPT) suspensions. We chose the compounds based on their inhibitory constants for mu- versus m-calpain, specificity of the inhibitors for calpain, and membrane permeability. Only three of the compounds inhibited calpain in RPT and were cytoprotective (Z-Leu-Phe-COOH, Z-Leu-Abu-CONH-CH(2)-CH(OH)-Ph, and Z-Leu-Phe-CONH-Et). Interestingly, Z-Leu-Phe-COOEt, Z-Leu-Abu-CONH-CH(2)-CH(OH)-C(6)F(5), and Z-Leu-Abu-CONH-CH(2)-2-quinolinyl were greater than 60% cytoprotective but did not inhibit calpain in RPT. Z-Leu-Abu-CONH(CH(2))(3)-morpholine was neither cytoprotective nor inhibited calpain. Although these results suggest that six of the seven peptide calpain inhibitors are cell permeable, only three of them inhibited calpain activity in RPT and were cytoprotective. Their ability to inhibit calpain or produce cytoprotection did not correlate with their ability to selectively inhibit purified mu- or m-calpain. Thus it remains to be determined whether they inhibit mu-calpain, m-calpain, or both in RPT. These results also suggest that inhibition of other protease(s) in addition to calpains may be responsible for the cytoprotective actions of some compounds.


Asunto(s)
Calpaína/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Túbulos Renales Proximales/efectos de los fármacos , Oligopéptidos/farmacología , Animales , Antimicina A , Muerte Celular/efectos de los fármacos , Permeabilidad de la Membrana Celular , Dipéptidos/farmacología , Femenino , Técnicas In Vitro , Isoenzimas/antagonistas & inhibidores , Túbulos Renales Proximales/citología , Túbulos Renales Proximales/enzimología , Conejos
9.
J Forensic Sci ; 20(2): 261-73, 1975 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1123596

RESUMEN

Illegal older model and foreign-made tear gas pen guns as well as illicitly manufactured pen guns were used to fire revolver or pistol cartridges of calibers .22, .25, .32, .38, .44 Special, and .44 magnum, as well as rifle cartridges of caliber .270. Velocity, range of accuracy, impact kinetic energy, and gelatin block penetrability of bullets fired from the various cartridges are presented. The characteristics of recovered bullets, cartridge casings, and firing pin impressions are described, and the hazards of these weapons to users and potential victims are discussed.


Asunto(s)
Criminología , Medicina Legal , Gases Lacrimógenos/efectos adversos , Heridas por Arma de Fuego , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...